DOCSLIB.ORG

Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M Review Molecular Cancer Therapeutics Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma Anke E.M. van Erp1, Yvonne M.H. Versleijen-Jonkers1, Winette T.A. van der Graaf1,2, and Emmy D.G. Fleuren3 Abstract Targeted therapies have revolutionized cancer treatment; in this regard, as this affects multiple hallmarks of cancer at however, progress lags behind in alveolar (ARMS) and embry- once. To determine the most promising and clinically relevant onal rhabdomyosarcoma (ERMS), a soft-tissue sarcoma mainly targeted therapy–based combination treatments for ARMS and occurring at pediatric and young adult age. Insulin-like growth ERMS, we provide an extensive overview of preclinical and factor 1 receptor (IGF1R)-directed targeted therapy is one of the (early) clinical data concerning a variety of targeted therapy– few single-agent treatments with clinical activity in these dis- based combination treatments. We concentrated on the most eases. However, clinical effects only occur in a small subset of common classes of targeted therapies investigated in rhabdo- patients and are often of short duration due to treatment myosarcoma to date, including those directed against receptor resistance. Rational selection of combination treatments of tyrosine kinases and associated downstream signaling path- either multiple targeted therapies or targeted therapies with ways, the Hedgehog signaling pathway, apoptosis pathway, chemotherapy could hypothetically circumvent treatment resis- DNA damage response, cell-cycle regulators, oncogenic fusion tance mechanisms and enhance clinical efficacy. Simultaneous proteins, and epigenetic modifiers. Mol Cancer Ther; 17(7); 1365–80. targeting of distinct mechanisms might be of particular interest Ó2018 AACR. Introduction treatment including surgery, chemotherapy, and radiotherapy has increased the 5-year overall survival (OS) to approximately Rhabdomyosarcoma is the most common type of soft-tissue 70%–90% for intermediate- and low-risk rhabdomyosarcoma, sarcoma (STS) observed in young patients with the most respectively. However, patients with high-risk rhabdomyosar- frequent subtypes being embryonal (ERMS) and alveolar rhab- coma still have a 5-year OS of <40%. In addition, treatment- domyosarcoma (ARMS). ERMS represents approximately 70% related toxicities severely decrease quality of life (1, 2). In an of childhood rhabdomyosarcoma and is most often observed attempt to increase survival and improve quality of life, the in the head and neck region and genitourinary track. ARMS is field of targeted therapy has gained substantial interest in seen in approximately 30% of rhabdomyosarcoma cases and rhabdomyosarcoma, and its potential is supported by various usually occurs in the deep tissue of the extremities. The majority lines of (pre)clinical research, which are mainly centered on of ARMS tumors are characterized by a fusion between PAX3 or targeted therapies originally developed for other tumor types. PAX7 on chromosome 2 and FOXO1 on chromosome 13 In the clinic, however, intrinsic and acquired resistance (80%). The remaining 20% are fusion negative. Although mechanisms have emerged as common pitfalls in rhabdomyo- generally ARMS have a poorer outcome compared with ERMS, sarcoma treatment. As such, increasing evidence exists that fusion-negative ARMS show a genetic profile similar to ERMS single-agent targeted therapy will not be sufficient to reach and an equally favorable clinical outcome. Multimodality clinical efficacy in patients with rhabdomyosarcoma. The cur- rent hypothesis is that combination therapy could enhance clinical efficacy and/or decrease treatment-associated toxicities. In this regard, simultaneous targeting of different mechanisms 1Department of Medical Oncology, Radboud University Medical Center, Nijme- gen, the Netherlands. 2The Institute of Cancer Research, Division of Clinical of action could be more effective as opposed to combining Studies, Clinical and Translational Sarcoma Research and The Royal Marsden inhibitors of similar classes, as the characteristic hallmarks of NHS Foundation Trust, Sutton, United Kingdom. 3The Institute of Cancer cancer illustrate that tumor progression is regulated by a wide Research, Division of Clinical Studies, Clinical and Translational Sarcoma variety of different processes. Research, Sutton, United Kingdom. To determine the most promising and clinically relevant Note: Supplementary data for this article are available at Molecular Cancer combination treatments for rhabdomyosarcoma, we reviewed Therapeutics Online (http://mct.aacrjournals.org/). the preclinical and (early) clinical trial data addressing combi- Corresponding Authors: Winette T.A. van der Graaf, Division of Clinical Studies, nations of targeted therapies or targeted therapy combined with The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, chemotherapy. We focused on the most common classes of 15 Cotswold Road, SM2 5NG, Sutton, United Kingdom. Phone: 4402-0872- targeted therapies investigated in rhabdomyosarcoma to date, 24448; Fax: þ31-24-36-15025; E-mail: [email protected]; and including those directed against receptor tyrosine kinases (RTK) Emmy D.G. Fleuren, emmy.fl[email protected] andassociateddownstreamsignaling pathways, the Hedgehog doi: 10.1158/1535-7163.MCT-17-1131 signaling pathway, apoptosis pathway, DNA damage response, Ó2018 American Association for Cancer Research. cell-cycle regulators, fusion proteins, and epigenetic modifiers. www.aacrjournals.org 1365 Downloaded from mct.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. van Erp et al. RTKs and a limited decrease of downstream AKT activity upon RTKs are membrane-bound proteins involved in signal trans- IGF1R antibody treatment. IGF1R antibodies combined with duction to the tumor cell. Activation by extracellular ligand recombinant IGFBP2, the PI3K inhibitor BKM130, or the binding or genetic mutations can lead to constitutive activity. mTOR inhibitor Ku-0063784 resensitized the resistant cell Intracellular signaling pathways, including the PI3K/AKT/mTOR, lines to IGF1R targeting (12). The possible low bioavailability RAS/MEK/ERK, and JAK/STAT3 pathway, are subsequently acti- of recombinant IGFBP2 could affect the clinical potential of vated. Several RTKs have been identified as possible targets for this particular combination treatment. Clinical trials did therapy in rhabdomyosarcoma, including the insulin-like growth show a partial response (PR) in a patient with IGF1R-positive factor 1 receptor (IGF1R), anaplastic lymphoma kinase (ALK), soft-tissue sarcoma and stable disease (SD) in 2 of 11 pediatric, platelet-derived growth factor receptors a and b (PDFGRa/b), adolescent, and young adult (AYA) patients with rhabdomyo- VEGFR, EGFR, and the fibroblast growth factor receptor 4 sarcoma for the combination of IGF1R inhibitors and mTOR (FGFR4; Fig. 1A; ref. 3). Despite the promising preclinical effects, inhibitors (Table 2; refs. 13–16). This shows that only a small clinical efficacy is limited and observed in small subsets of pati- group responded to treatment and one study showed that the ents (4, 5). Combination treatment might enhance the clinical addition of temsirolimus led to increased toxicity without a efficacy of RTK-targeted therapies (Table 1). clear increase in efficacy in most patients (15). Nevertheless, these data do show that combined targeted therapy can over- IGF1R/ALK. One way of optimizing IGF1R treatment might be come primary treatment resistance and suggest that, when its combination with other (R)TK inhibitors. As coexpression of given simultaneously, might delay or prevent treatment resis- the RTKs IGF1R and ALK has been described in rhabdomyo- tance altogether. sarcoma, this may present a rational combination. In vitro, Because chemotherapy remains fundamental in rhabdomyo- combined anti-IGF1R antibody R1507 and ALK inhibitor sarcoma treatment, combinations with chemotherapy have TAE684 treatment showed synergism in ARMS cell lines. In been investigated. In young patients with ARMS and ERMS, ERMS, however, no enhanced effect was observed (6). In ARMS, the combination of the IGF1R antibody cixutumumab with the characteristic PAX3-FOXO1 protein can enhance IGF1R conventional chemotherapy was compared with the combina- and ALK transcription, possibly explaining this difference in tion of temozolomide with conventional chemotherapy. The sensitivity. However, we, among others, could not find intrinsic combination with cixutumumab led to a higher percentage ALK activity in rhabdomyosarcoma cells (7–9). In addition, the of patients reaching an 18-month event-free survival (EFS; antitumor effects observed with the ALK inhibitor ceritinib cixutumumab 68% vs. temozolomide 39%; NCT01055314; were mostly explained by its capacity to inhibit IGF1R signaling Table 2). Of note, the combination with cixutumumab had (9). Combined treatment of ceritinib with the multikinase more reports of high-grade toxicity compared with the combi- inhibitor sorafenib showed synergistic effect in vitro (8). In nation with temozolomide. High-grade toxicities were, how- addition, we observed high activity of the signaling protein Src ever, only observed in a very small group (3/97, 3%), leaving post ceritinib treatment in both subtypes, and combined treat- the combination with cixutumumab preferential to the combi- ment of ceritinib and the Src inhibitor dasatinib was synergistic nation with temozolomide (17). Although preclinical research in vitro (9).
Load more

Recommended publications
  • Genetic Screens in Isogenic Mammalian Cell Lines Without Single Cell Cloning
    ARTICLE https://doi.org/10.1038/s41467-020-14620-6 OPEN Genetic screens in isogenic mammalian cell lines without single cell cloning Peter C. DeWeirdt1,2, Annabel K. Sangree1,2, Ruth E. Hanna1,2, Kendall R. Sanson1,2, Mudra Hegde 1, Christine Strand 1, Nicole S. Persky1 & John G. Doench 1* Isogenic pairs of cell lines, which differ by a single genetic modification, are powerful tools for understanding gene function. Generating such pairs of mammalian cells, however, is labor- 1234567890():,; intensive, time-consuming, and, in some cell types, essentially impossible. Here, we present an approach to create isogenic pairs of cells that avoids single cell cloning, and screen these pairs with genome-wide CRISPR-Cas9 libraries to generate genetic interaction maps. We query the anti-apoptotic genes BCL2L1 and MCL1, and the DNA damage repair gene PARP1, identifying both expected and uncharacterized buffering and synthetic lethal interactions. Additionally, we compare acute CRISPR-based knockout, single cell clones, and small- molecule inhibition. We observe that, while the approaches provide largely overlapping information, differences emerge, highlighting an important consideration when employing genetic screens to identify and characterize potential drug targets. We anticipate that this methodology will be broadly useful to comprehensively study gene function across many contexts. 1 Genetic Perturbation Platform, Broad Institute of MIT and Harvard, 75 Ames Street, Cambridge, MA 02142, USA. 2These authors contributed equally: Peter C. DeWeirdt,
    [Show full text]
  • The Role of PARP1 in Monocyte and Macrophage
    cells Review The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors Maciej Sobczak 1, Marharyta Zyma 2 and Agnieszka Robaszkiewicz 1,* 1 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] 2 Department of Immunopathology, Medical University of Lodz, 7/9 Zeligowskiego, Bldg 2, Rm177, 90-752 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-42-6354449; Fax: +48-42-6354449 or +48-42-635-4473 Received: 4 August 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Modulation of PARP1 expression, changes in its enzymatic activity, post-translational modifications, and inflammasome-dependent cleavage play an important role in the development of monocytes and numerous subtypes of highly specialized macrophages. Transcription of PARP1 is governed by the proliferation status of cells at each step of their development. Higher abundance of PARP1 in embryonic stem cells and in hematopoietic precursors supports their self-renewal and pluri-/multipotency, whereas a low level of the enzyme in monocytes determines the pattern of surface receptors and signal transducers that are functionally linked to the NFκB pathway. In macrophages, the involvement of PARP1 in regulation of transcription, signaling, inflammasome activity, metabolism, and redox balance supports macrophage polarization towards the pro-inflammatory phenotype (M1), which drives host defense against pathogens. On the other hand, it seems to limit the development of a variety of subsets of anti-inflammatory myeloid effectors (M2), which help to remove tissue debris and achieve healing.
    [Show full text]
  • An Overview of the Role of Hdacs in Cancer Immunotherapy
    International Journal of Molecular Sciences Review Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy Debarati Banik, Sara Moufarrij and Alejandro Villagra * Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, 800 22nd St NW, Suite 8880, Washington, DC 20052, USA; [email protected] (D.B.); [email protected] (S.M.) * Correspondence: [email protected]; Tel.: +(202)-994-9547 Received: 22 March 2019; Accepted: 28 April 2019; Published: 7 May 2019 Abstract: Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration.
    [Show full text]
  • Primary Mixed Myosarcoma of the Uterine Tube: a Case Report and Review of the Literature ALEXANDER S
    Med. J. 258 CASE REPORT: MYOSAIRCOMAMYOSARCOMA OFUTERINEOF UTERINE TUBE Canad.Feb. 3, 1968, Ass.vol. 98 dans 1'cesophage superieur. Le plus petit malade REFERENCES chez qui une biopsie fut prelevee pesait 13 livres 1. CROSBY, W. H.: Amer. or. Dig. Dis., 8: 2, 1963. 2. CAREY, J. B., JR.: Gastroenterology, 46: 550, 1964. et 6tait age de 9 mois. 3. BECK, L T. et al.: Bull. Gastroint. EBndosc., 11: 15, 1965. We wish to thank 0. H. Kimbell, Ph.D., H. Robidoux- 4. MCDONALD, W. G.: Gastroenterology, 51: 390, 1966. 5. PARTIN, J. C. AND SCHUBERT, W. K: New Eng. J. Poirier, R.N., R.-M. Leblanc, R.N., D. Michaud, R.N., Med., 274: 94, 1966. and Marc Gigu6re, R.B.P., for their co-operation and 6. KUITUNEN, P. AND VISAKORPI, J. K.: Lancet, 1: 1276, active assistance. 1965. Primary Mixed Myosarcoma of the Uterine Tube: A Case Report and Review of the Literature ALEXANDER S. ULLMANN, M.D. and MAERIT B. KALLET, M.D., Detroit, Mich., U.S.A. SINCE primary malignant neoplasms of the uterine tube are so rare that no one indi- vidual or clinic has been able to study a large series of patients, the importance of reporting every case has often been emphasized.2-4 Although over 800 cases of primary carcinoma of the tube have been described in the liter- ature,4 up to 1956 only 30 authentic cases of primary sarcoma had been reported and to this number Abrams added another one.1' 8 Recently we had the opportunity to study a patient with primary sarcoma of the fallopian tube.
    [Show full text]
  • PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide
    Published OnlineFirst October 5, 2015; DOI: 10.1158/1535-7163.MCT-15-0587 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway Florian Engert1, Cornelius Schneider1, Lilly Magdalena Weib1,2,3, Marie Probst1,and Simone Fulda1,2,3 Abstract Ewing sarcoma has recently been reported to be sensitive to that subsequent to DNA damage-imposed checkpoint activa- poly(ADP)-ribose polymerase (PARP) inhibitors. Searching for tion and G2 cell-cycle arrest, olaparib/TMZ cotreatment causes synergistic drug combinations, we tested several PARP inhibi- downregulation of the antiapoptotic protein MCL-1, followed by tors (talazoparib, niraparib, olaparib, veliparib) together with activation of the proapoptotic proteins BAX and BAK, mitochon- chemotherapeutics. Here, we report that PARP inhibitors syner- drial outer membrane permeabilization (MOMP), activation of gize with temozolomide (TMZ) or SN-38 to induce apoptosis caspases, and caspase-dependent cell death. Overexpression of a and also somewhat enhance the cytotoxicity of doxorubicin, nondegradable MCL-1 mutant or BCL-2, knockdown of NOXA or etoposide, or ifosfamide, whereas actinomycin D and vincris- BAX and BAK, or the caspase inhibitor N-benzyloxycarbonyl-Val- tine show little synergism. Furthermore, triple therapy of ola- Ala-Asp-fluoromethylketone (zVAD.fmk) all significantly reduce parib, TMZ, and SN-38 is significantly more effective compared olaparib/TMZ-mediated apoptosis. These findings emphasize with double or monotherapy. Mechanistic studies revealed that the role of PARP inhibitors for chemosensitization of Ewing the mitochondrial pathway of apoptosis plays a critical role in sarcoma with important implications for further (pre)clinical mediating the synergy of PARP inhibition and TMZ.
    [Show full text]
  • Management of Chronic Myelogenous Leukemia in Pregnancy
    ANTICANCER RESEARCH 35: 1-12 (2015) Review Management of Chronic Myelogenous Leukemia in Pregnancy AMIT BHANDARI, KATRINA ROLEN and BINAY KUMAR SHAH Cancer Center and Blood Institute, St. Joseph Regional Medical Center, Lewiston, ID, U.S.A. Abstract. Discovery of tyrosine kinase inhibitors has led to Leukemia in pregnancy is a rare condition, with an annual improvement in survival of chronic myelogenous leukemia incidence of 1-2/100,000 pregnancies (8). Since the first (CML) patients. Many young CML patients encounter administration of imatinib (the first of the TKIs) to patients pregnancy during their lifetime. Tyrosine kinase inhibitors with CML in June 1998, it is estimated that there have now inhibit several proteins that are known to have important been 250,000 patient years of exposure to the drug (mostly functions in gonadal development, implantation and fetal in patients with CML) (9). TKIs not only target BCR-ABL development, thus increasing the risk of embryo toxicities. tyrosine kinase but also c-kit, platelet derived growth factors Studies have shown imatinib to be embryotoxic in animals with receptors α and β (PDGFR-α/β), ARG and c-FMS (10). varying effects in fertility. Since pregnancy is rare in CML, Several of these proteins are known to have functions that there are no randomized controlled trials to address the may be important in gonadal development, implantation and optimal management of this condition. However, there are fetal development (11-15). Despite this fact, there is still only several case reports and case series on CML in pregnancy. At limited information on the effects of imatinib on fertility the present time, there is no consensus on how to manage and/or pregnancy.
    [Show full text]
  • Uterine Carcinosarcoma Associated with Pelvic Radiotherapy for Sacral Chordoma: a Case Report
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Available online at www.sciencedirect.com Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 89e92 www.tjog-online.com Case Report Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: A case report Korhan Kahraman a,*, Fırat Ortac a, Duygu Kankaya b, Gulsah Aynaoglu a a Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey b Department of Pathology, Ankara University School of Medicine, Ankara, Turkey Accepted 28 December 2010 Abstract Objective: Postirradiation sarcoma of the female genital tract is rare, but a recognized event. Most reported cases have been associated with history of radiotherapy for various gynecologic conditions, particularly cancer of the uterine cervix and abnormal uterine bleeding. The occurrence of uterine sarcoma secondary to radiotherapy for a non-gynecologic tumor and, furthermore, this condition being simultaneous with the recurrence of primary tumor is unique. Case Report: A 67-year-old woman presented with a uterine mass which was diagnosed as a sarcoma by endometrial curettage and history of pelvic radiotherapy 23 years previously for sacral chordoma. Surgical staging procedure for uterine malignancy was performed. The final pathologic diagnosis was carcinosarcoma of the uterus. Conclusion: In uterine masses seen in patients with history of irradiation to the pelvic field, the probability of uterine sarcomas should always be kept in mind. These tumors may occur simultaneously with recurrence of primary tumor previously treated by adjuvant radiation therapy. Copyright Ó 2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC.
    [Show full text]
  • Diagnostic Immunohistochemistry for Canine Cutaneous Round Cell Tumours — Retrospective Analysis of 60 Cases
    FOLIA HISTOCHEMICA ORIGINAL PAPER ET CYTOBIOLOGICA Vol. 57, No. 3, 2019 pp. 146–154 Diagnostic immunohistochemistry for canine cutaneous round cell tumours — retrospective analysis of 60 cases Katarzyna Pazdzior-Czapula, Mateusz Mikiewicz, Michal Gesek, Cezary Zwolinski, Iwona Otrocka-Domagala Department of Pathological Anatomy, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland Abstract Introduction. Canine cutaneous round cell tumours (CCRCTs) include various benign and malignant neoplastic processes. Due to their similar morphology, the diagnosis of CCRCTs based on histopathological examination alone can be challenging, often necessitating ancillary immunohistochemical (IHC) analysis. This study presents a retrospective analysis of CCRCTs. Materials and methods. This study includes 60 cases of CCRCTs, including 55 solitary and 5 multiple tumours, evaluated immunohistochemically using a basic antibody panel (MHCII, CD18, Iba1, CD3, CD79a, CD20 and mast cell tryptase) and, when appropriate, extended antibody panel (vimentin, desmin, a-SMA, S-100, melan-A and pan-keratin). Additionally, histochemical stainings (May-Grünwald-Giemsa and methyl green pyronine) were performed. Results. IHC analysis using a basic antibody panel revealed 27 cases of histiocytoma, one case of histiocytic sarcoma, 18 cases of cutaneous lymphoma of either T-cell (CD3+) or B-cell (CD79a+) origin, 5 cases of plas- macytoma, and 4 cases of mast cell tumours. The extended antibody panel revealed 2 cases of alveolar rhabdo- myosarcoma, 2 cases of amelanotic melanoma, and one case of glomus tumour. Conclusions. Both canine cutaneous histiocytoma and cutaneous lymphoma should be considered at the beginning of differential diagnosis for CCRCTs. While most poorly differentiated CCRCTs can be diagnosed immunohis- tochemically using 1–4 basic antibodies, some require a broad antibody panel, including mesenchymal, epithelial, myogenic, and melanocytic markers.
    [Show full text]
  • R&D Briefing 76
    The Impact of Recent Regulatory Developments on the Mexican Therapeutic Landscape Access to innovative medicines is key to El acceso a medicamentos innovadores es clave para improving overall population health, reducing mejorar la salud de toda la población, para reducir los hospitalisation time and decreasing morbidity and tiempos de hospitalización, la morbilidad y la mortalidad mortality. An efficient regulatory process can be de un país. Un proceso regulatorio eficiente tiene un reflected in measurable positive health impacts; impacto positivo medible en la salud, y por el contrario, conversely, activities that slow or impede acciones que retrasan o impiden la eficiencia regulatoria y regulatory efficiency and predictability can be su predictibilidad pueden ser perjudiciales. La parálisis detrimental. Recent developments in the Mexican reciente del Sistema regulatorio mexicano respecto a la regulatory system for the assessments of evaluación de nuevos medicamentos innovadores innovative new products have had a negative conlleva un impacto negativo en la salud de la población impact on Mexican public health. mexicana. This Briefing addresses the impact of suspending Este informe analiza el impacto de la suspensión de las the activities of the New Molecules Committee actividades del Comité de Moléculas Nuevas (NMC, por (NMC) on the Mexican therapeutic landscape. sus siglas en inglés) sobre el horizonte terapéutico de First, we compared the way that “new medicines” México. En primer lugar, comparamos la definición de are defined within the context of the Mexican nuevos medicamentos según el contexto regulatorio regulatory system, with definitions used by mexicano con las definiciones adoptadas por otras comparable regulators and health organisations. agencias reguladoras u organizaciones de salud del We have also investigated the extent to which mundo.
    [Show full text]
  • Misdiagnosed Infantile Rhabdomyofibrosarcoma: a Case Report
    2766 ONCOLOGY LETTERS 12: 2766-2768, 2016 Misdiagnosed infantile rhabdomyofibrosarcoma: A case report TAO PAN1*, KEN CHEN1*, RUN-SONG JIANG2 and ZHENG‑YAN ZHAO2 Departments of 1General Surgery and 2Reconstructive Plastic Surgery, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China Received January 19, 2015; Accepted February 16, 2016 DOI: 10.3892/ol.2016.5032 Abstract. Infantile rhabdomyofibrosarcoma is a rare form of infantile fibrosarcoma has uniform, solidly‑packed spindle cells soft‑tissue tumor often associated with difficulties in diagnosis. arranged in a fascicular or herringbone pattern similar to the The disease is positioned intermediately between rhabdo- vascular pattern observed with hemangiopericytoma (4). Infan- myosarcoma and infantile fibrosarcoma in terms of clinical tile rhabdomyofibrosarcoma may be identified as childhood presentation, immunohistochemistry, behavior, morphology spindle‑cell sarcoma with a low degree of rhabdoid differentiation and ultrastructural features. Reports of rhabdomyofibrosarcoma and aggressive clinical behavior (5). Overlooking the diagnosis cases are limited in the literature. The present case describes a of infantile rhabdomyofibrosarcoma may increase the chances 26‑month‑old female who presented with a slowly progressive, of local recurrence or metastatic disease; therefore, aggressive soft‑tissue mass in the right chest wall. The mass was success- multimodality treatment is required for these patients (6). Reports fully treated with surgery. Using histopathology, the tumor was of rhabdomyofibrosarcoma cases are limited in the literature. diagnosed and classified as infantile rhabdomyofibrosarcoma. The present case report describes a 26‑month‑old patient who The patient has been followed‑up for 2 years and is currently presented with a slowly progressive, soft‑tissue mass in the right in good condition.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
    Lindström and Friedman BMC Cancer (2020) 20:397 https://doi.org/10.1186/s12885-020-06782-9 RESEARCH ARTICLE Open Access The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib H. Jonathan G. Lindström and Ran Friedman* Abstract Background: Chronic myeloid leukaemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which inhibits the T315I mutation of BCR-ABL1, a main source of drug resistance, and (II) Asciminib, which has been developed as an allosteric BCR-ABL1 inhibitor, targeting an entirely different binding site, and as such does not compete for binding with other drugs. These drugs offer new treatment options. Methods: We measured the proliferation of KCL-22 cells exposed to imatinib–dasatinib, imatinib–asciminib and dasatinib–asciminib combinations and calculated combination index graphs for each case. Moreover, using the median–effect equation we calculated how much axitinib can reduce the growth advantage of T315I mutant clones in combination with available drugs. In addition, we calculated how much the total drug burden could be reduced by combinations using asciminib and other drugs, and evaluated which mutations such combinations might be sensitive to. Results: Asciminib had synergistic interactions with imatinib or dasatinib in KCL-22 cells at high degrees of inhibition. Interestingly, some antagonism between asciminib and the other drugs was present at lower degrees on inhibition.
    [Show full text]